Dr. Reddy’s Laboratories Limited (REDY) (Q4FY23)
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments.
The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business.
The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Dr. Reddy’s Laboratories has ventured into the trade generics business, launching its dedicated division called RGenX. Trade generics are directly distributed through wholesalers and are not marketed as branded medicines. This move aligns with Dr. Reddy’s Laboratories’ larger goal of reaching over 1.5bn patients by the year 2030.
Dr. Reddy’s Laboratories’ stock price showed an upward trend in past 3-months. It increased by 5.97% during the period. The stock price increased by 12.39% during the last 1 year. The stock has a 52-week high of ₹5,273.15 and its 52-week low is ₹3,997.
In the past 3 years, the stock has given returns of 29.11%. REDY has a 50-day moving Avg. and 200-day moving Avg. of ₹4,801.61 and ₹4,556.66, respectively.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals
– Price Performance
Stock Price Performance
No of Pages: 35
To download the previous quarter’s equity report CLICK HERE
To Download other equity/ stock reports CLICK HERE
Follow our LinkedIn page for more updates